ReviewFrontiers in immunology2025
New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The onset and relapse of autoimmune diseases (AIDs) are triggered by autoimmune attacks on target tissues. However, symptoms are unlikely to appear if damaged cells are rapidly replaced. Addressing the implications of this premise, the present work examines the balance between target tissue destruction and recovery rates as a key factor in the mechanisms of remissions and relapses in AIDs. The theory, supported by published clinical data, suggests that remissions are improbable in AIDs characterized by slow target tissue recovery. Conversely, a high recovery rate is a necessary (though not sufficient) condition for cycles of remission and relapse in AIDs. A high recovery rate of target tissue explains the tendency for remitting-relapsing disease, the likelihood of detecting autoantibodies in healthy individuals and the responsiveness to immunosuppressive drug treatments. Analyzing specific AIDs through the balance of tissue destruction and recovery yields several insights. For example, the difference between androgenic alopecia, a non-remitting-relapsing disease and alopecia areata, a remitting-relapsing AID, is elucidated. A new mechanism underlying relapses and remissions in alopecia areata based on hair follicle regeneration rate is proposed. It is suggested that mild Graves' disease and remitting Hashimoto's thyroiditis would be responsive to corticosteroids or immunosuppressant treatment, unlike more severe forms of these diseases. Additionally, it is proposed that the transition from remitting-relapsing multiple sclerosis to secondary progressive multiple sclerosis is associated with the depletion of brain compensatory reserves. Notably, it is concluded that exercise will not play a neuroprotective role in secondary progressive multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.